Illumina Inc ILMN

NAS: ILMN | ISIN: US4523271090   23/09/2026
255,38 USD (+3,20%)
(+3,20%)   23/09/2026

6 september 2026 · AI-favoriet Bloom Energy en genomicapionier Illumina komen in S&P500 · Tijd.be (€)

De nieuwe, toekomstige leden van de S&P500 gaan een sterke beurssessie tegemoet. Zo'n 20.000 miljard dollar is op de of andere manier gekoppeld aan de beursbarometer.

30 juli 2026 · Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026 · Persbericht

16 juli 2026 · Illumina expands Billion Cell Atlas program with new AI drug developers · Persbericht

9 juli 2026 · Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026 · Persbericht

9 juli 2026 · Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer · Persbericht

23 juni 2026 · Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors · Persbericht

8 juni 2026 · Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution · Persbericht

28 mei 2026 · Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research · Persbericht

28 mei 2026 · Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research · Persbericht

21 mei 2026 · David P. King elected to Illumina's Board of Directors · Persbericht

19 mei 2026 · Illumina releases 2025 Corporate Responsibility Report, expanding access to genomics and accelerating global impact · Persbericht

30 april 2026 · Illumina Reports Financial Results for First Quarter of Fiscal Year 2026 · Persbericht

16 april 2026 · DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows · Persbericht

14 april 2026 · Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease · Persbericht

9 april 2026 · Illumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026 · Persbericht

2 april 2026 · Illumina Announces Changes to Board of Directors · Persbericht

18 maart 2026 · Illumina and Labcorp expand collaboration to broaden access to precision oncology testing · Persbericht

16 maart 2026 · Illumina advances preventive genomics through strategic consortium with Veritas Genetics · Persbericht

5 maart 2026 · Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering · Persbericht

27 februari 2026 · Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida · Persbericht

Mijn selecties